McDonnell Boehnen Hulbert & Berghoff LLP partner Kevin Noonan, Ph.D. authors a May 2019 DDNews article entitled, “Patent Docs: A Solution in Search of a Problem.” On March 8, a bipartisan group of senators introduced S.659, entitled “The Biologic Patent Transparency Act.” These senators (Collins, R-ME; Kaine, D-VA; Portman, R-OH; Shaheen, D-NH; Braun, R-IN; and Stabenow, D-MI) are ostensibly motivated by a desire to reduce prescription drug prices (according to their websites) and have focused on differences between the Biologics Price Competition and Innovation Act (BPCIA) and the Hatch Waxman Act that, in their view, reduces “transparency” over purported bases of biologic drug prices to the public’s detriment. View the article